Log in

NYSE:IQV - Iqvia Stock Price, Forecast & News

$107.14
-3.41 (-3.08 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$100.89
Now: $107.14
$108.45
50-Day Range
$84.00
MA: $136.79
$166.11
52-Week Range
$81.79
Now: $107.14
$169.14
Volume3.06 million shs
Average Volume1.93 million shs
Market Capitalization$20.61 billion
P/E Ratio110.45
Dividend YieldN/A
Beta0.94
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Read More
Iqvia logo

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorBusiness Services
CUSIPN/A
Phone919-998-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.09 billion
Cash Flow$12.65 per share
Book Value$32.28 per share

Profitability

Net Income$191 million

Miscellaneous

Employees67,000
Market Cap$20.61 billion
Next Earnings Date5/6/2020 (Estimated)
OptionableOptionable

Receive IQV News and Ratings via Email

Sign-up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.


Iqvia (NYSE:IQV) Frequently Asked Questions

How has Iqvia's stock been impacted by COVID-19 (Coronavirus)?

Iqvia's stock was trading at $125.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IQV stock has decreased by 14.6% and is now trading at $107.14. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Iqvia?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Iqvia.

When is Iqvia's next earnings date?

Iqvia is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for Iqvia.

How were Iqvia's earnings last quarter?

Iqvia Holdings Inc (NYSE:IQV) announced its quarterly earnings data on Wednesday, February, 12th. The medical research company reported $1.74 EPS for the quarter, topping analysts' consensus estimates of $1.72 by $0.02. The medical research company had revenue of $2.90 billion for the quarter, compared to analysts' expectations of $2.85 billion. Iqvia had a net margin of 1.72% and a return on equity of 17.65%. Iqvia's revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.50 EPS. View Iqvia's earnings history.

What guidance has Iqvia issued on next quarter's earnings?

Iqvia issued an update on its FY20 earnings guidance on Wednesday, February, 12th. The company provided earnings per share guidance of $7.15-7.35 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.22. The company issued revenue guidance of 11.775-12.000 billion, compared to the consensus revenue estimate of $11.84 billion.

What price target have analysts set for IQV?

17 Wall Street analysts have issued 12 month target prices for Iqvia's stock. Their forecasts range from $110.00 to $200.00. On average, they anticipate Iqvia's share price to reach $168.25 in the next twelve months. This suggests a possible upside of 57.0% from the stock's current price. View analysts' price targets for Iqvia.

Has Iqvia been receiving favorable news coverage?

News stories about IQV stock have trended very positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Iqvia earned a daily sentiment score of 4.0 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutIqvia.

Are investors shorting Iqvia?

Iqvia saw a decrease in short interest in the month of March. As of March 13th, there was short interest totaling 2,777,500 shares, a decrease of 22.2% from the February 27th total of 3,570,000 shares. Based on an average daily volume of 1,500,000 shares, the days-to-cover ratio is presently 1.9 days. Approximately 1.5% of the shares of the stock are short sold. View Iqvia's Current Options Chain.

Who are some of Iqvia's key competitors?

What other stocks do shareholders of Iqvia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), Allergan (AGN) and salesforce.com (CRM).

Who are Iqvia's key executives?

Iqvia's management team includes the following people:
  • Mr. Ari Bousbib, Chairman, Pres & CEO (Age 58)
  • Mr. Michael R. McDonnell, Exec. VP & CFO (Age 55)
  • Mr. Eric M. Sherbet, Exec. VP, Gen. Counsel & Sec. (Age 55)
  • Mr. W. Richard Staub III, Pres of R&D Solutions (Age 56)
  • Mr. Kevin C. Knightly, Pres of Information & Technology Solutions (Age 58)

What is Iqvia's stock symbol?

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Who are Iqvia's major shareholders?

Iqvia's stock is owned by a number of institutional and retail investors. Top institutional investors include State Street Corp (4.02%), Jackson Square Partners LLC (2.68%), FMR LLC (2.16%), Janus Henderson Group PLC (2.13%), Alliancebernstein L.P. (2.02%) and Capital Research Global Investors (1.78%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Group Holdings (Sbs) Advis Tpg, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View institutional ownership trends for Iqvia.

Which institutional investors are selling Iqvia stock?

IQV stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Farallon Capital Management LLC, Renaissance Technologies LLC, Citigroup Inc., DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, AMF Pensionsforsakring AB, First Trust Advisors LP, and Jackson Square Partners LLC. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, John Connaughton, Kevin C Knightly, Michael J Evanisko, and Michael R Mcdonnell. View insider buying and selling activity for Iqvia.

Which institutional investors are buying Iqvia stock?

IQV stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, AustralianSuper Pty Ltd, Goldman Sachs Group Inc., Point72 Asset Management L.P., Loomis Sayles & Co. L P, Bessemer Group Inc., Assenagon Asset Management S.A., and Alliancebernstein L.P.. View insider buying and selling activity for Iqvia.

How do I buy shares of Iqvia?

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Iqvia's stock price today?

One share of IQV stock can currently be purchased for approximately $107.14.

How big of a company is Iqvia?

Iqvia has a market capitalization of $20.61 billion and generates $11.09 billion in revenue each year. The medical research company earns $191 million in net income (profit) each year or $5.94 on an earnings per share basis. Iqvia employs 67,000 workers across the globe. View additional information about Iqvia.

What is Iqvia's official website?

The official website for Iqvia is http://www.iqvia.com/.

How can I contact Iqvia?

Iqvia's mailing address is 4820 EMPEROR BLVD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]


MarketBeat Community Rating for Iqvia (NYSE IQV)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  504 (Vote Outperform)
Underperform Votes:  446 (Vote Underperform)
Total Votes:  950
MarketBeat's community ratings are surveys of what our community members think about Iqvia and other stocks. Vote "Outperform" if you believe IQV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IQV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel